银屑病生物制剂安全性:荟萃分析未反映真实风险
BACKGROUND: In reported systematic reviews and meta-analyses of randomized controlled trials (RCTs) assessing treatments for psoriasis, the proportion of serious adverse events (SAEs) did not differ between treatments and placebo.…
要点
- 将银屑病恶化计入严重不良事件会掩盖生物制剂的真实风险。
- 剔除恶化病例后,生物制剂严重不良事件风险显著高于安慰剂。
核心结论
- 剔除银屑病恶化病例后,生物制剂组严重不良事件风险高于安慰剂组。
- 因事件罕见,无法明确严重不良事件风险升高是否与特别关注的不良事件相关。
- 建议临床试验分别报告导致住院的疾病恶化和其他严重不良事件以提高透明度。
研究设计与样本
- 系统评价与荟萃分析,从Living Network Cochrane Review的140项随机对照试验中选取比较生物制剂与安慰剂的试验。
- 共分析51项随机对照试验,包括21项含抗TNF-α组、15项含抗IL-17组、11项含抗IL-23组和9项含抗IL-12/23组。
- 主要结局为剔除银屑病恶化病例后治疗组与安慰剂组的严重不良事件数。
- 研究注册于PROSPERO(CRD42019124495)。
临床怎么用
- 解读生物制剂安全性数据时需注意严重不良事件是否包含银屑病恶化。
- 临床决策中应关注剔除疾病恶化后的严重不良事件风险。
局限性
- 特别关注的不良事件事件数少,无法分析其与严重不良事件风险的关联。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In reported systematic reviews and meta-analyses of randomized controlled trials (RCTs) assessing treatments for psoriasis, the proportion of serious adverse events (SAEs) did not differ between treatments and placebo. Including cases of psoriasis worsening as SAEs may explain the lack of difference. OBJECTIVES: This systematic review and meta-analysis aimed to explore this possibility. METHODS: Among the 140 RCTs included in the Living Network Cochrane Review (last search on 8 May 2019), we selected those comparing a biologic treatment against placebo. The primary outcome was the numbers of SAEs in the treatment and placebo arms after excluding cases of psoriasis worsening. Secondary outcomes were the number of adverse events (AEs) of special interest. The trial was registered on PROSPERO (CRD42019124495). RESULTS: We analysed 51 RCTs. Of these, 21 included at least one anti-tumour necrosis factor (TNF)-α arm, 15 one anti-interleukin (IL)-17 arm, 11 one anti-IL-23 arm and nine one anti-IL-12/23 arm. With cases of psoriasis worsening included, the risk of occurrence of SAEs between biologic treatments and placebo did not differ: risk ratio (RR) 1·09, 95% confidence interval (CI) 0·88-1·36. After excluding cases of psoriasis worsening, the RR became significant (RR 1·30, 95% CI 1·02-1·65). By drug class, the RRs were for anti-TNF-α, 1·68 (95% CI 1·11-2·54; no missing data); anti-IL-17, 1·28 (95% CI 0·88-1·85; no missing data); anti-IL-23, 0·95 (95% CI 0·59-1·52; no missing data) and anti-IL-12/23, 1·18 (95% CI 0·72-1·94; no missing data). We were unable to examine potential differences in AEs of special interest between biologic treatments and placebo arms because of the small number of events. CONCLUSIONS: On excluding cases of worsening psoriasis, the risk of occurrence of SAEs is higher in the biologic than in the placebo arm. Given the rare events, we could not highlight whether this higher risk of SAEs was related to AEs of special interest. Reporting of SAEs in clinical trials has to be changed to provide more transparency through the separate reporting of disease flares leading to hospital admission and other SAEs.
引用
- Afach S, Chaimani A, Evrenoglou T, et al. Meta-analysis results do not reflect the real safety of biologics in psoriasis. Br J Dermatol. 2020. PMID: 32446286. doi:10.1111/bjd.19244
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。